Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of once-daily co-trimoxazole 960 mg in tuberculosis patients
NL-OMON40570Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trimethoprim + sulfamethoxazole in Tuberculosis (TB), sponsored by University Medical Center Groningen. Primary endpoint: Pharmacokinetic variability of co-trimoxazole. Started Oct 2013; status: active, not recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON40570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40570.